Investigacion

María Jesús Sanz Ferrando

María Jesús Sanz Ferrando
María Jesús Sanz Ferrando

María Jesús Sanz Ferrando

Dr. Sanz is a permanent Senior Professor of Pharmacology at the University of Valencia and is co-director of the Inflammation Research Group at the INCLIVA Health Research Institute. She has been President of the Spanish Pharmacology Society since 2014. 

Her main line of research focuses on clarifying the mechanisms involved in the pro-inflammatory activity of angiotensin-II (Ang-II) and its modulation, more specifically, the mechanisms involved in the interactions between mononuclear cells and the arterial endothelium resulting from endothelial dysfunction caused by Ang II. Her group also studies the impact of systemic inflammation on the development of cardiovascular pathologies; the group has already characterized the vascular inflammation caused by menopause and other risk factors for atherosclerosis including diabetes, chronic obstructive pulmonary disease (COPD), etc. Her work has been published in journals such as Circulation, Circulation Research, Blood, PNAS, the Journal of Immunology, Arteriosclerosis Thrombosis and Vascular Biology, Thorax, Cardiovascular Research, and the British Journal of Pharmacology, among others. 

She has published a total of 93 original articles in indexed journals, 2 reviews, and 9 book chapters. Regarding her indexed journal articles, 70% have been published in journals in the Q1 category and of these 38% of are in the D1 category. She has an h-index of 33 and she has received a total of 2008 citations. In addition, she has given a total of 25 invited presentations and seminars at national and international forums. 

She has been a visiting academic at numerous different foreign research centers including the National heart and lung institute at Imperial College, London (3 years and 2 months) and the Immunology Science Research Group, University of Calgary, Calgary, Canada (1 year and 9 months). She has also directed 10 doctoral theses and has secured continued funding as a Principal Investigator since 1999 in national and local competitive convocations. 

She is part of the European Union’s COST (European Cooperation in Science and Technology) action and also belongs to the WHRI-ACADEMY (William Harvey International Translational Research Academy) consortium’s COFUND (Co-funding of regional, national, and international programmes) program. She was an associate in Biomedicine at the National Evaluation and Foresight Agency (ANEP; Agencia Nacional de Evaluación y Prospectiva) between 2009 and 2013 and has evaluated projects for different national agencies (including ANEP, the Carlos III Health Institute Healthcare Research Fund [FIS; Fondo de Investigación Sanitaria], Castile and Leon University System’s Quality-Assurance Agency [ACSUCyL; Agencia para la Calidad del Sistema Universitario de Castilla y León], Catalonian regional governmental Management Agency for University Grants and Research [AGAUR; Agència de Gestió d'Ajuts Universitaris i de Recerca], and the Andalusian Government) and international agencies (Canada Foundation for Innovation). 

She is reviewer for international journals (Circulation Research, Blood, PNAS, Journal of Immunology, Arteriosclerosis Thrombosis and Vascular Biology, the British Journal of Pharmacology, etc.) and is on the Editorial Board of other journals.